This gender-independent detection of cell-free fetal DNA in maternal plasma using RASSF1A/β-actin has curtained off a new dimension regarding its utility to predict the adverse pregnancy outcomes. Recent efforts have been directed at developing sequences from cell-free fetal DNA (cffDNA) as markers for pregnancy outcomes. The utility of cffDNA using the methylation-dependent DSCR3 and RASSF1A markers along with total cell-free DNA (cf-DNA) in maternal serum by HYP2 marker are useful in predicting adverse pregnancy outcomes. Increased amount (>95th percentile) of cffDNA fraction in the second trimester is associated with preterm birth. Indigenously developed low-cost method of the gender-independent sequence markers from cffDNA was investigated and evaluated with the standardized commercial kits as predictive markers for adverse pregnancy outcomes. Our results indicated that indigenously developed method for detection of geneder-independent cffDNA can be applicable for screening test of adverse pregnancy outcome.

中文翻译：

---

一项前瞻性研究，旨在评估无细胞胎儿DNA（cffDNA）浓度中性别独立序列的人口统计学变异，并通过基于非试剂盒的经济方法来预测妊娠结局

使用RASSF1A /β-肌动蛋白的这种性别独立的检测母体血浆中无细胞胎儿DNA的方法，为预测不良妊娠结局的实用性开辟了一个新领域。最近的努力已针对从无细胞胎儿DNA（cffDNA）开发序列作为妊娠结局的标志物。使用HYP2标记使用甲基化依赖性DSCR3和RASSF1A标记以及孕妇血清中的总无细胞DNA（cf-DNA）来使用cffDNA有助于预测不良妊娠结局。妊娠中期cffDNA分数增加（> 95％）与早产有关。研究和评估了标准化的商业试剂盒中作为cffDNA性别独立序列标记的本地开发低成本方法，作为不良妊娠结局的预测标记。我们的结果表明，本地开发的检测独立于性别的cffDNA的方法可适用于不良妊娠结局的筛查测试。